<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83736">
  <stage>Registered</stage>
  <submitdate>19/03/2009</submitdate>
  <approvaldate>27/04/2009</approvaldate>
  <actrnumber>ACTRN12609000213246</actrnumber>
  <trial_identification>
    <studytitle>Safety study of a test oral iron chelator in male iron-overloaded patients</studytitle>
    <scientifictitle>A Dose-Escalation, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701 in Iron-Overloaded Male Patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Iron overload in transfusion-dependent patients</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose (6 mg/kg,  10 mg/kg, 16 mg/kg or 32 mg/kg) of FBS0701 administered orally</interventions>
    <comparator>Patient 1: 6 mg/kg FBS0701
Patient 2: 10 mg/kg FBS0701
Patient 3: 16 mg/kg FBS0701
Patient 4: 32 mg/kg FBS0701</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the safety and pharmacokinetics of FBS0701</outcome>
      <timepoint>Safety assessments and blood sampling for pharmacokinetic analysis will be preformed whilst patients are confined in the clinical facility for 24 hours, followed by visits at 36, 48  and 72 hours following dosing.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine dose-proportionality of ascending doses of FBS0701 by frequent blood sampling and urine collection, and pharmacokinetic analyses.  Thirteeen blood samples will be taken during the first 12 hours following dosing on Day 1 of the study.  Blood samples will then be taken every 12 hours to 48 hours following dosing, and then a final sample on Day 4 of the study.  A continuous urine collection for 24 hours will occur following dosing.</outcome>
      <timepoint>For 72 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To characterise pharmacodynamics of FBS0701 by measuring urinary iron and magnesium.</outcome>
      <timepoint>For 72 hours post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Trasnfusion-dependent patients wo have transfusional overload, requiring chronic treatment with deferoxamine, deferasirox or deferiprone.  Patients must be willing to discontinue all existing iron chelation therapies for a minimum of seven days prior to admission to clinic.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Received or is anticipated to receive a new prescription systemic or topical medication within 14 days of study start, or over-the-counter medications within 48 hours.  Any condition that would interfere with drug absorption (ie chronic diarrhoea).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>FerroKin BioSciences Inc.</primarysponsorname>
    <primarysponsoraddress>2729 Debbie Court
San Carlos
CA 94070</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>FerroKin BioSciences Inc.</fundingname>
      <fundingaddress>2729 Debbie Court
San Carlos
CA 94070</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This aim of this study is to assess the safety of different doses of anovel orally-administered iron chelator in patients with iron-overload.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>18/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>DR HUGH YOUNG RIENHOFF, JR</name>
      <address>2729 Debbie Court
San Carlos
CA 94070</address>
      <phone>+1-408-677-0682</phone>
      <fax>+1-508-848-3058</fax>
      <email>hrienhoff@datahooks.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>CAMERON JOHNSON</name>
      <address>CMAX, Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide, SA, 5000</address>
      <phone>+61 8 8222-3931</phone>
      <fax>+61 8 8223-3475</fax>
      <email>cameron.johnson@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>JANE KELLY</name>
      <address>CMAX
274 Melbourne Street
North Adelaide  SA  5006</address>
      <phone>+61 8 8416-3100</phone>
      <fax>+61 8 8361-8615</fax>
      <email>jane.kelly@cmax.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>